•  
  •  
 

Article Type

Original Study

Abstract

Background: Gastric cancer is a significant health issue worldwide; it ranks fourth among cancers, following those of the lung, breast, and colon. Tumor markers can be utilized as screening and diagnostic tests for neoplastic diseases. Aim: This study aims to evaluate value and the efficacy of tumor markers (CA242, CA19-9, CEA) in patients with gastric carcinoma and to investigate the utility of single and combined tumor markers for the diagnosis of gastric carcinoma. Methods: The serum level of CA242, CA19-9, and CEA were measured in 40 patients with gastric carcinoma, using the ELISA technique, compared with 20 patients with benign gastric conditions and 20 healthy controls. Chi-square tests and F-test were employed for statistical analysis. Results: The mean age of patients with gastric cancer was 54.7 ± 12.8 years, with a male-to-female ratio of approximately 1.2:1. Serological data indicated that 60%, 37.5%, and 50% of these patients had positive results for CA242, CA19-9, and CEA, respectively. A statistically significant difference was observed in the mean serum level of CA19-9 between gastric cancer patients and controls. Additionally, CA242 demonstrated the best sensitivity (CA242 71%), while CA19-9 exhibited the highest specificity. The combination of tumor markers (CA19-9 and CEA), (CA242 and CEA), and (CEA and CA19-9) increased specificity to 97%. Conclusion: The novel tumor marker CA242 was the most sensitive for gastric cancer while CA19-9 was the most specific. Furthermore, a significant increase in serum CA19-9 levels was of diagnostic value. The combination of two tumor markers enhanced the specificity of the test.

Keywords

tumor marker, CA242, CA19-9, CEA, adenocarcinoma of stomach

Creative Commons License

Creative Commons Attribution-NonCommercial 4.0 International License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Download

Share

COinS